COMPARE THE EVIDENCE

Liraglutide

Findings, possible implications, and reported experiences.

About Liraglutide

PeptideMetabolism

Primary research area: Emerging research
Regulatory status: Research status varies
Evidence level: Evidence level not yet characterized
Primary mechanism: Mechanism not yet characterized

Reference profile available · Coverage varies by section

Also known as Saxenda · Victoza

Liraglutide is a GLP-1 receptor agonist that regulates blood glucose through glucose-dependent insulin and glucagon effects. [1]

What has been observed?

Selected source-linked reading notes, not the complete literature or a pooled conclusion.

Human · Abstract reviewed

How did liraglutide perform in STEP 8?

Daily liraglutide 3 mg versus weekly semaglutide 2.4 mg.

Mean weight reduction was 6.4%, versus 15.8% with semaglutide at 68 weeks.

Limits & adverse findings: These results apply to the tested regimens in adults without diabetes. Treatment discontinuation for any reason: 27.6% versus 13.5% with semaglutide.

Open primary source · Read interpretation separately

Explore outcomes for this compound

Uses & research: The cited Victoza label covers type 2 diabetes and reduction of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. [1]
Known half-life: Approximately 13 hours after administration under the skin in the Victoza label. [1]
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Evidence & important limits: Indications vary by product. The Victoza label includes gastrointestinal adverse reactions, pancreatitis warnings and a boxed warning about thyroid C-cell tumors observed in rodents. [1]

Safety & evidence boundaries

Source-specific information, not a personal safety clearance or monitoring plan.

Indications vary by product. The Victoza label includes gastrointestinal adverse reactions, pancreatitis warnings and a boxed warning about thyroid C-cell tumors observed in rodents.

Victoza prescribing information

Human study: Treatment discontinuation for any reason: 27.6% versus 13.5% with semaglutide. Source

Explore safety questions by system

These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.

Heart, blood pressure & lipids Liver injury Kidney function Glucose effects Reproductive & endocrine effects Mood & sleep Adverse effects & interactions

Interactions, rare harms, long-term effects and reversibility require separate evidence. Do not infer they are absent when the sources here do not address them.

Identity, names & formulations

Canonical compound: Liraglutide · liraglutide

Searchable names: Saxenda, Victoza

Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.

Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.

Understand the evidence types

Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.

Randomized human trials: Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
Controlled human studies: Use a comparison group; allocation and confounding still matter.
Prospective human research: Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
Observational human research: Describes associations. Confounding can explain differences.
Case reports and series: Useful for unusual events and safety signals, not reliable rates or effect sizes.
Animal research: Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
Cell and tissue research: Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
Mechanistic and computational evidence: Helps explain or predict a pathway; predictions need experimental and clinical testing.
Anecdotal reports: Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.

Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.

Sources for this profile

1. Victoza prescribing information Drug label · indications, warnings and clinical pharmacology

Reference facts checked 2026-09-16. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.

Browse all studies

Research outcomeResearch model

Study model describes the source. Confidence depends on methods, replication, population and outcome.

Loading compound research…